{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:53Z","timestamp":1791327353794,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10072-025-08372-8","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T02:19:49Z","timestamp":1753064389000},"page":"4515-4526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study."],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-5545","authenticated-orcid":false,"given":"Marco","family":"Bolchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ceccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Schiano di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Di Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"8372_CR1","unstructured":"Pescador Ruschel MA, De Jesus O, Migraine H (2023) Feb 13. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013. PMID: 32809622"},{"key":"8372_CR2","doi-asserted-by":"publisher","unstructured":"Silberstein SD, Migraine (2004) Lancet. ;363(9406):381\u2009\u2013\u200991. https:\/\/doi.org\/10.1016\/S0140-6736(04)15440-8. PMID: 15070571","DOI":"10.1016\/S0140-6736(04)15440-8"},{"issue":"10283","key":"8372_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7Epub 2021 Mar 25. PMID: 33773613","journal-title":"Lancet"},{"key":"8372_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30299-5","author":"GBD 2015 Neurological Disorders Collaborator Group","year":"2017","unstructured":"GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990\u20132015: a. Lancet Neurol 16(11):877\u2013897. https:\/\/doi.org\/10.1016\/S1474-4422(17)30299-5Epub 2017 Sep 17. PMID: 28931491; PMCID: PMC5641502 systematic analysis for the Global Burden of Disease Study 2015"},{"key":"8372_CR5","doi-asserted-by":"publisher","unstructured":"GBD2016DandIIandPC (2017) Global, regional, and National incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2. Erratum in: Lancet. 2017;390(10106):e38. PMID: 28919117; PMCID: PMC5605509","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"8372_CR6","doi-asserted-by":"publisher","unstructured":"Scher AI, Bigal ME, Lipton RB (2005) Comorbidity of migraine. Curr Opin Neurol. ;18(3):305\u2009\u2013\u200910. https:\/\/doi.org\/10.1097\/01.wco.0000169750.52406.a2. PMID: 15891417","DOI":"10.1097\/01.wco.0000169750.52406.a2"},{"issue":"6","key":"8372_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1212\/01.WNL.0000154528.21485.3A","volume":"64","author":"T Kurth","year":"2005","unstructured":"Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, Diener HC, Buring JE (2005) Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64(6):1020\u20131026","journal-title":"Neurology"},{"issue":"7","key":"8372_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.neurol.2021.06.004","volume":"177","author":"G Demarquay","year":"2021","unstructured":"Demarquay G, Rheims S (2021) Relationships between migraine and epilepsy: pathophysiological mechanisms and clinical implications. Rev Neurol (Paris) 177(7):791\u2013800","journal-title":"Rev Neurol (Paris)"},{"key":"8372_CR9","doi-asserted-by":"publisher","unstructured":"Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, quality of life, and depression: a population-based case-control study. Neurology. ;55(5):629\u2009\u2013\u200935. https:\/\/doi.org\/10.1212\/wnl.55.5.629. PMID: 10980724","DOI":"10.1212\/wnl.55.5.629"},{"key":"8372_CR10","doi-asserted-by":"publisher","unstructured":"Peck KR, Smitherman TA, Baskin SM (2015) Traditional and alternative treatments for depression: implications for migraine management. Headache. ;55(2):351-5. https:\/\/doi.org\/10.1111\/head.12521. Epub 2015 Feb 3. PMID: 25644990","DOI":"10.1111\/head.12521"},{"key":"8372_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jad.2015.02.032","volume":"178","author":"M Fornaro","year":"2015","unstructured":"Fornaro M, Stubbs B (2015) A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder. J Affect Disord 178:88\u201397. https:\/\/doi.org\/10.1016\/j.jad.2015.02.032Epub 2015 Mar 9. PMID: 25801521","journal-title":"J Affect Disord"},{"key":"8372_CR12","doi-asserted-by":"publisher","unstructured":"Breslau N (1998) Psychiatric comorbidity in migraine. Cephalalgia. ;18 Suppl 22:56\u2009\u2013\u20098; discussion 58\u201361. https:\/\/doi.org\/10.1177\/0333102498018s2210. PMID: 9793713","DOI":"10.1177\/0333102498018s2210"},{"key":"8372_CR13","doi-asserted-by":"publisher","unstructured":"McWilliams LA, Goodwin RD, Cox BJ (2004) Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. ;111(1\u20132):77\u201383. https:\/\/doi.org\/10.1016\/j.pain.2004.06.002. PMID: 15327811","DOI":"10.1016\/j.pain.2004.06.002"},{"issue":"1","key":"8372_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/head.12004","volume":"53","author":"TA Smitherman","year":"2013","unstructured":"Smitherman TA, Kolivas ED, Bailey JR (2013) Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache 53(1):23\u201345. https:\/\/doi.org\/10.1111\/head.12004Epub 2012 Dec 26. PMID: 23278473","journal-title":"Headache"},{"key":"8372_CR15","doi-asserted-by":"publisher","unstructured":"Cevoli S, Giannini G, Favoni V, Pierangeli G, Cortelli P (2012) Migraine and sleep disorders. Neurol Sci. ;33 Suppl 1:S43-6. https:\/\/doi.org\/10.1007\/s10072-012-1030-0. PMID: 22644169","DOI":"10.1007\/s10072-012-1030-0"},{"key":"8372_CR16","doi-asserted-by":"publisher","unstructured":"Kelman L, Rains JC Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005 Jul-Aug;45(7):904\u2009\u2013\u200910. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05159.x. PMID: 15985108","DOI":"10.1111\/j.1526-4610.2005.05159.x"},{"issue":"9","key":"8372_CR17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/head.13911","volume":"60","author":"TA Pearl","year":"2020","unstructured":"Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ (2020) Impact of depression and anxiety symptoms on Patient-Reported outcomes in patients with migraine: results from the American registry for migraine research (ARMR). Headache 60(9):1910\u20131919. https:\/\/doi.org\/10.1111\/head.13911Epub 2020 Aug 4. PMID: 32749685","journal-title":"Headache"},{"issue":"8","key":"8372_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","volume":"13","author":"S Ashina","year":"2012","unstructured":"Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC (2012) Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 13(8):615\u2013624. https:\/\/doi.org\/10.1007\/s10194-012-0479-9Epub 2012 Sep 25. PMID: 23007859; PMCID: PMC3484253","journal-title":"J Headache Pain"},{"issue":"7","key":"8372_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De Dhaem O, Van Kroon A, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87(7):741\u2013749. https:\/\/doi.org\/10.1136\/jnnp-2015-312233Epub 2016 Jan 5. PMID: 26733600","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"8372_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.pain.2005.09.010","volume":"118","author":"M Lant\u00e9ri-Minet","year":"2005","unstructured":"Lant\u00e9ri-Minet M, Radat F, Chautard MH, Lucas C (2005) Anxiety and depression associated with migraine: influence on migraine subjects\u2019 disability and quality of life, and acute migraine management. Pain 118(3):319\u2013326. https:\/\/doi.org\/10.1016\/j.pain.2005.09.010Epub 2005 Nov 14. PMID: 16289799","journal-title":"Pain"},{"issue":"1","key":"8372_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u2009\u2013\u20092022 update. J Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-xPMID: 35690723; PMCID: PMC9188162","journal-title":"J Headache Pain"},{"issue":"4","key":"8372_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61(4):662\u2013672. https:\/\/doi.org\/10.1111\/head.14097PMID: 33891348; PMCID: PMC8251795","journal-title":"Headache"},{"key":"8372_CR23","doi-asserted-by":"publisher","unstructured":"Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D\u2019Souza DN, Pearlman EM. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and\/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, Pooled (2020) EVOLVE-1 and EVOLVE-2 Studies. Headache. ;60(10):2202\u20132219. https:\/\/doi.org\/10.1111\/head.13970. Epub 2020 Oct 16. Erratum in: Headache. 2022;62(1):114\u2013116. PMID: 33063862; PMCID: PMC7756873","DOI":"10.1111\/head.13970"},{"key":"8372_CR24","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"8372_CR25","doi-asserted-by":"publisher","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. ;56(6 Suppl 1):S20-8. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20. PMID: 11294956","DOI":"10.1212\/wnl.56.suppl_1.s20"},{"key":"8372_CR26","doi-asserted-by":"publisher","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. ;12(8):963\u2009\u2013\u200974. https:\/\/doi.org\/10.1023\/a:1026119331193. PMID: 14651415","DOI":"10.1023\/a:1026119331193"},{"issue":"6","key":"8372_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483 PMID: 1593914","journal-title":"Med Care"},{"key":"8372_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","volume":"12","author":"WWK Zung","year":"1971","unstructured":"Zung WWK (1971) A rating instrument for anxiety disorders. Psychosomatics 12:371\u2013379","journal-title":"Psychosomatics"},{"key":"8372_CR29","doi-asserted-by":"publisher","unstructured":"Beck At W, Ch, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry. ;4:561\u2009\u2013\u200971. https:\/\/doi.org\/10.1001\/archpsyc.1961.01710120031004. PMID: 13688369","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"issue":"8","key":"8372_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455\u2013464. https:\/\/doi.org\/10.1038\/nrneurol.2016.93Epub 2016 Jul 8. PMID: 27389092","journal-title":"Nat Rev Neurol"},{"key":"8372_CR31","doi-asserted-by":"publisher","unstructured":"Amoozegar F (2017) Depression comorbidity in migraine. Int Rev Psychiatry. ;29(5):504\u2013515. https:\/\/doi.org\/10.1080\/09540261.2017.1326882. Epub 2017 Jul 6. PMID: 28681617","DOI":"10.1080\/09540261.2017.1326882"},{"key":"8372_CR32","doi-asserted-by":"publisher","unstructured":"Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression (or for chronic daily headaches)--clinical lessons. Headache. ;46 Suppl 3:S144-6. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00566.x. PMID: 17034393","DOI":"10.1111\/j.1526-4610.2006.00566.x"},{"issue":"1\u20132","key":"8372_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pain.2009.06.019","volume":"146","author":"BD Heckman","year":"2009","unstructured":"Heckman BD, Holroyd KA, Himawan L, O\u2019Donnell FJ, Tietjen G, Utley C, Stillman M (2009) Do psychiatric comorbidities influence headache treatment outcomes? Results of a naturalistic longitudinal treatment study. Pain 146(1\u20132):56\u201364. https:\/\/doi.org\/10.1016\/j.pain.2009.06.019Epub 2009 Aug 5. PMID: 19660866; PMCID: PMC2791689","journal-title":"Pain"},{"issue":"5","key":"8372_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/head.14460","volume":"63","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Sandoe CH, Ford JH, Hand AL, Jedynak JP, Port MD, Detke HC (2023) Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study. Headache 63(5):683\u2013691. https:\/\/doi.org\/10.1111\/head.14460Epub 2023 Feb 16. PMID: 36797223","journal-title":"Headache"},{"issue":"1","key":"8372_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","volume":"23","author":"M Silvestro","year":"2022","unstructured":"Silvestro M, Tessitore A, Orologio I, De Micco R, Tartaglione L, Trojsi F, Tedeschi G, Russo A (2022) Galcanezumab effect on whole pain burden and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain 23(1):69. https:\/\/doi.org\/10.1186\/s10194-022-01436-6PMID: 35698070; PMCID: PMC9195341","journal-title":"J Headache Pain"},{"issue":"10","key":"8372_CR36","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1177\/0333102418789072","volume":"38","author":"DC Buse","year":"2018","unstructured":"Buse DC, Lipton RB, Hallstr\u00f6m Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2018) Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia 38(10):1622\u20131631","journal-title":"Cephalalgia"},{"issue":"1\u20132","key":"8372_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.psychres.2015.06.009","volume":"229","author":"M Furtado","year":"2015","unstructured":"Furtado M, Katzman MA (2015) Examining the role of neuroinflammation in major depression. Psychiatry Res 229(1\u20132):27\u201336. https:\/\/doi.org\/10.1016\/j.psychres.2015.06.009Epub 2015 Jun 21. PMID: 26187338","journal-title":"Psychiatry Res"},{"key":"8372_CR38","doi-asserted-by":"publisher","unstructured":"Vanmolkot FH, de Hoon JN (2007) Increased C-reactive protein in young adult patients with migraine. Cephalalgia. ;27(7):843-6. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01324.x. PMID: 17668468","DOI":"10.1111\/j.1468-2982.2007.01324.x"},{"key":"8372_CR39","doi-asserted-by":"publisher","unstructured":"de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM (2023) Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol. Oct 17. https:\/\/doi.org\/10.1111\/ene.16106. Epub ahead of print. PMID: 37847221","DOI":"10.1111\/ene.16106"},{"issue":"2","key":"8372_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res 52(2):69\u201377","journal-title":"J Psychosom Res"},{"key":"8372_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measur 1:385\u2013401","journal-title":"Appl Psychol Measur"},{"key":"8372_CR42","doi-asserted-by":"publisher","unstructured":"Math\u00e9 AA, Agren H, Lindstr\u00f6m L, Theodorsson E (1994) Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neurosci Lett. ;182(2):138\u2009\u2013\u200942. https:\/\/doi.org\/10.1016\/0304-3940(94)90782-x. PMID: 7715797","DOI":"10.1016\/0304-3940(94)90782-x"},{"issue":"11","key":"8372_CR43","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/cns.12835","volume":"24","author":"FF Zhang","year":"2018","unstructured":"Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY (2018) Brain structure alterations in depression: psychoradiological evidence. CNS Neurosci Ther 24(11):994\u20131003","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"8372_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0278-5846(01)00219-6","volume":"26","author":"AA Math\u00e9","year":"2002","unstructured":"Math\u00e9 AA, Agren H, Wallin A, Blennow K (2002) Calcitonin gene-related peptide and calcitonin in the CSF of patients with dementia and depression: possible disease markers. Prog Neuropsychopharmacol Biol Psychiatry 26(1):41\u201348","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"8372_CR45","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamaneurol.2025.0806","volume":"82","author":"RB Lipton","year":"2025","unstructured":"Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, Galic M, Mitsikostas D, Tassorelli C, Denysenko L, Cohen JM (2025) Fremanezumab for the treatment of patients with migraine and comorbid major depressive disorder: the UNITE randomized clinical trial. JAMA Neurol 82(6):560\u2013569","journal-title":"JAMA Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08372-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08372-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:59:53Z","timestamp":1757260793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08372-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["8372"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08372-8","relation":{"references":[{"id-type":"doi","id":"10.1016\/S1474-4422(17)30299-5","asserted-by":"subject"}]},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from ethics committee of the ASST Spedali Civili Hospital, Brescia, Italy, NP 3949, approved on 10 August 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained for anonymized patient information to be published in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Francesca Schiano di Cola has received speaker honoraria from Eli-Lilly, Lundbeck, and Novartis. Renata Rao has received speaker honoraria from Eli-Lilly, Novartis, Lundbeck, and Teva. Alessandro Padovani is a consultant, has served on the scientific advisory board of GE Healthcare, Eli-Lilly, and Actelion Ltd. Pharmaceuticals, and has received speaker honoraria from Nutricia, PIAM, Langstone Technology, GE Healthcare, Lilly, Lundbeck, UCB Pharma, and Chiesi Pharmaceuticals. He is funded by a grant from the Ministry of the University (MURST).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}